Trevi Therapeutics To Present Data From Ph2a CANAL Trial At The ERS Congress 2024
Portfolio Pulse from Benzinga Newsdesk
Trevi Therapeutics will present data from its Phase 2a CANAL trial at the ERS Congress 2024, focusing on the effects of nalbuphine ER on chronic cough in IPF patients.
September 04, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Trevi Therapeutics is set to present promising data from its Phase 2a CANAL trial at the ERS Congress 2024, which could positively impact its stock price.
The presentation of Phase 2a trial data at a major congress like ERS 2024 suggests potential positive developments for Trevi's investigational therapy, which could lead to increased investor interest and a positive impact on TRVI's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100